Background
==========

Cervical cancer, the second most common cancer in women, occurs around the world. It has a high incidence and mortality, especially in middle- and low-income countries. The number of cervical cancer cases is estimated to have increased by 14% from 2000 to 2005 in China \[[@b1-medscimonit-21-1276]\]. Although the 5-year overall survival rate of advanced cervical cancer patients has increased with the development of radiotherapy and chemotherapy, radioresistance and metastasis are still the difficulties for radiation oncologists because tumors, even with similar pathological pattern and stage, are not equally sensitive to radiation. Some studies had shown that radiation therapy is closely related to gene susceptibility \[[@b2-medscimonit-21-1276],[@b3-medscimonit-21-1276]\]. Several radioresistance-associated genes such as HIF-1 and p53 had been investigated, but the exact mechanism of radioresistance is not known. Thus, identifying the molecular basis of cervical cancer radioresistance is of vital importance and may lead to novel radiosensitive strategies.

In this study, we investigate the differential expression genes in the tumor tissues before and after radiotherapy by the whole human genome oligo microarray. The expression level of the differential expression genes was performed by hierarchical clustering. We also analyzed the potential functions of the interested genes. We screened-out a list of genes that might be closely related to radioresistance and the related pathways by above methods. Our results may provide targets for the development of radiosensitive drugs and set individualized treatment for advanced cervical cancer.

Material and Methods
====================

Patients and treatment
----------------------

From January 2005 to October 2007, 135 women with cervical squamous cell carcinoma were treated with radiotherapy at the Department of Radiotherapy, Fuzhou General Hospital. Patients without integrated follow-up were excluded. A total of 130 patients had undergone whole-course radiotherapy were included in this study. Approval by the Institutional Review Board of Fu Zhou General Hospital was obtained in advance, and the informed consent requirement was waived because the current study was performed by retrospective review, but the informed consent of the other 3 patients with staged IIIB in 2012 was obtained because the data of these patients were analyzed prospectively. None of the enrolled patients had underlying disease that would influence survival.

Patients with advanced cervical cancer (stage IIB-IVA) underwent radiotherapy. The radiotherapy protocols included a 30Gy whole pelvic irradiation and a subsequent 20 Gy central shield irradiation. The total dose of intracavity irradiation to Point A was 36--48 Gy. Concurrent chemoradiation was conducted by 2 cycles of platinum-based chemotherapy in all patients. The radiotherapy protocols were performed according to the NCCN guideline (2004). The machines were Varian600C/D medical linear accelerators.

We obtained the tumor samples prior to radiotherapy by punch biopsy. The samples were fixed in 10% formalin and embedded in paraffin. The paraffin-embedded sections were cut into 5-mm sections and processed for H+E staining, as well as histochemical and immunohistochemical studies. Residual tumor tissues of 3 patients undergoing a total 50 Gy dose of radiotherapy were also obtained by punch biopsy. One part of these tumor tissues was used for RNA detection and the other part was processed the same as in pre-radiotherapy.

The patients were followed up every 3 months in the first 2 years, every 6 months in the third year, and every year afterwards. Imageological, ultrasonic, and blood examinations were performed to observe local recurrence at every follow-up. International Federation of Gynecology and Obstetrics (FIGO) staging system were used to evaluate the clinical staging. The retrospective research data were obtained from hospital records.

Total RNA extraction and oligonucleotide array sequence analysis
----------------------------------------------------------------

Total RNA was extracted from tumor tissues of 3 patients before radiotherapy and residual tumor tissues after a total radiotherapy dose of 50 Gy obtained by punch biopsy using TRIZOL Reagent (Cat\#15596-018, Life Technologies, Carlsbad, CA, US) following the manufacturer's instructions and checked for an RIN number to inspect RNA integrity by an Agilent Bioanalyzer 2100. The integrity of all RNA samples was verified with 2100 RIN ≥7.0 and 28S/18S ≥0.7. Qualified total RNA was further purified by use of the RNeasy micro kit (Cat\#74004, QIAGEN, GmBH, Germany) and RNase-Free DNase Set (Cat\#79254, QIAGEN, GmBH, Germany).

The samples were amplified, labeled, and purified by using GeneChip 3′IVT Express Kit (Cat\#901229, Affymetrix, Santa Clara, CA, USA) followed the manufacturer's instructions to obtain biotin-labeled cDNA. Array hybridization and washing was performed using GeneChip® Hybridization, Wash and Stain Kit (Cat\#900720, Affymetrix, Santa Clara, CA, USA) in a Hybridization Oven 645 (Cat\#00-0331-220V, Affymetrix, Santa Clara, CA, USA) and Fluidics Station 450 (Cat\#00-0079, Affymetrix, Santa Clara, CA, USA) following the manufacturer's instructions. Slides were scanned by a GeneChip® Scanner 3000 (Cat\#00-00212, Affymetrix, Santa Clara, CA, US) and Command Console Software 3.1 (Affymetrix, Santa Clara, CA, US) with default settings. Raw data were normalized by RMA algorithm, Gene Spring Software 11.0 (Agilent Technologies, Santa Clara, CA, US).

Quantitative real-time PCR
--------------------------

To validate the results of microarray data, real-time PCR was performed. Six genes were used as an internal control: CXCL12, CD74, FGF7, COL14A1, PRC1, and RAD54L. Primer sequences used for real-time PCR are shown in [Table 1](#t1-medscimonit-21-1276){ref-type="table"}.

PCR was performed as follows: 95°C for 5 min; 40 cycles of 95°C for 30 s, annealing temperature 56--58°C for 90 s, and 72°C for 60 s. The PCR products were separated on a 2% agarose gel, visualized with ethidium bromide staining, and photographed with FAS-III Series (NIPPON Genetics Co., Ltd., Tokyo, Japan). We used the MiniOpticon Real-Time PCR Detection System (Bio-Rad, Hercules, CA) for real-time PCR. Relative quantification of PCR products was calculated after normalization to β-actin.

Histochemical and immunohistochemical analyses
----------------------------------------------

Xylene was used to deparaffinize the tissue blocks sections. The sections were then rehydrated in a descending ethanol series. Finally, they were rinsed with water and incubated for 30 min in 0.3% hydrogen peroxide in methanol. The serial sections were incubated with primary anti-CXCL12 in a humid chamber at 4°C overnight. They were then rinsed in PBS, and incubated for 1 h with a horseradish peroxidase-conjugated secondary antibody.

Immunohistologic expression was assessed by 2 expert pathologists independently without knowledge of clinical outcome. The positive cell degree was expressed using a scale from 0 to 4: (−) represents 0%; (+) represents 1--25%; (++) represents 26--50%; (+++) represents 51--75%, and (++++) represents 76--100%.

We conducted survival analysis on 130 patients. The length of time from the date of radiotherapy ending to the date of death or the last follow-up was defined as the overall survival (OS) time.

Statistical analyses
--------------------

SPSS 18.0 for windows were performed. Survival was estimated using the Kaplan-Meier method. We used the log-rank test to analyze the factors of survival time for any significant differences. Predictors of clinical radioresistance were identified by logistic regression analysis. Cox's regression analysis was used to calculate the prognostic significance of individual parameters. The χ^2^ test and Fisher's exact test were used to evaluate differences in proportions. When the P value was below 0.05, the difference was considered to be significant.

Results
=======

Patients' characteristics
-------------------------

The characteristics of 130 patients are listed in [Table 2](#t2-medscimonit-21-1276){ref-type="table"}. The mean patient age was 53.7, ranging from 35 to 78. The median follow-up time in surviving patients was 68 months.

Gene expression analysis and clustering
---------------------------------------

Microarray quality control verified the expression of all the samples to be qualified ([Table 3](#t3-medscimonit-21-1276){ref-type="table"}). The differential expression genes were identified by hierarchical clustering map analysis ([Figure 1](#f1-medscimonit-21-1276){ref-type="fig"}). There were 111 up-regulated and 127 down-regulated genes among a total of 238 differentiated genes that exhibited ≥3.0-fold change and p\<0.05 were identified with 111 up-regulated and 127 down-regulated ([Tables 4](#t4-medscimonit-21-1276){ref-type="table"}, [5](#t5-medscimonit-21-1276){ref-type="table"}).

Quantitative RT-PCR validate the gene expression results
--------------------------------------------------------

As shown in [Figure 2](#f2-medscimonit-21-1276){ref-type="fig"}, [Tables 1](#t1-medscimonit-21-1276){ref-type="table"} and [6](#t6-medscimonit-21-1276){ref-type="table"} highly differentially expressed genes -- CXCL12, CD74, FGF7, COL14A1, PRC1, and RAD54L -- were selected to verify the microarray results. These results were highly correlated with the microarray data. The above data strongly supported the reliability of the microarray results.

Validation of protein expression and analysis of the relationship between CXCL12 expression and survival rate
-------------------------------------------------------------------------------------------------------------

We detected the expression of CXCL12 protein with immunohistochemistry on 130 paraffin-embedded samples. The gene expression results were confirmed at the protein level. Immunolocalization with anti-CXCL12 antibody largely showed positive staining in the cell membrane and cytoplasm of cancer cells ([Figure 3](#f3-medscimonit-21-1276){ref-type="fig"}). The CXCL12 positive cell ratio was 61.5%. No correlation was found between the expression of CXCL12 and several clinicopathological factors, including age, sex, FIGO stage, tumor size, and treatment program ([Table 6](#t6-medscimonit-21-1276){ref-type="table"}). We found that CXCL12 was an independent risk factor by Kaplan-Meier survival analysis. CXCL12 was strongly correlated with a poor prognosis. The death risk ratio of patients with positive CXCL12 expression to negative expression is 3.07. There was a significant difference between the groups (p=0.035) ([Figure 4](#f4-medscimonit-21-1276){ref-type="fig"}, [Table 7](#t7-medscimonit-21-1276){ref-type="table"}).

Expression of CXCL12 in tumor tissues before radiotherapy and residual tumor tissues after a radiotherapy dose of 50 Gy
-----------------------------------------------------------------------------------------------------------------------

RNA was extracted from tumor tissues of 5 patients with stage IIIB cervical cancer before radiotherapy and after a radiotherapy dose of 50 Gy. The expression of CXCL12 was detected. As shown in [Figure 5](#f5-medscimonit-21-1276){ref-type="fig"}, the increasing mRNA expression of CXCL12 occurred in residual tissues with the ratio of 35.3.

Discussion
==========

Radiation therapy is an effective radical approach for advanced cervical cancer; however, not every patient has good response to irradiation, which might be an important cause of local recurrence or metastasis. Thus identifying the radioresistance-associated genes and making individual radiotherapy schedules could enhance the clinical outcomes. High-density oligonucleotide and cDNA microarrays, which are the high-throughput technologies for assaying gene expression, may identify the differential expression of genes in tumor tissues before and after radiotherapy. In this study, we revealed 127 highly differentially expressed genes involved in processes such as cell cycling, cell apoptosis, cell signaling, and cell adhesion. The changed expression genes of residual tumor tissues-derived may mean high metastasis and radioresistance in cervical cancer.

The chemokine family is among the significantly differentially expressed genes that participate in tumor growth and metastasis \[[@b4-medscimonit-21-1276]\]. CXCL12, a member of a superfamily of small pro-inflammatory chemoattractant cytokines, was first cloned from a bone marrow-derived stromal cell line. Several studies have shown that CXCL12 expression was correlated with poor prognosis in various cancers such as breast cancer, lung cancer, colorectal cancer, and endometrial cancer \[[@b5-medscimonit-21-1276]--[@b7-medscimonit-21-1276]\]. DNA-damaging agents such as irradiation or chemotherapeutics could increase CXCL12 expression. Wolff et al. found that the CXCL12 expression had significant alternations in head and neck squamous cell carcinoma cell lines after X-ray irradiation \[[@b8-medscimonit-21-1276]\]. Shu-Chi Wang et al. \[[@b9-medscimonit-21-1276]\] found that a significant increase in CXCL12 expression occurred at 24 h after irradiation in murine astrocytoma tumor cell lines and also found that radiotherapy could increase the microvascular density (MVD) and the CXCL12 expression of shrunken brain tumor tissues after a dose of 8 Gy or 15 Gy. They thought these results indicated that local brain irradiation effectively reduced the growth rate of the primary tumor, but promoted tumor invasiveness. These factors might increase the complexity of gliomas following radiation therapy. Similar to their results, we also found that the expression of CXCL12 increased significantly in residual tumor tissues after an irradiation dose of 50 Gy. We found that CXCL12 was an independent risk factor by a Kaplan-Meier survival analysis. CXCL12 was strongly correlated with a poor prognosis. In our opinion, the mechanism of CXCL12 in radioresistance might be as follows: CXCL12 might be a bidirectional cue that attracted T cells at low concentrations and repelled them at high concentrations \[[@b10-medscimonit-21-1276]\]. When a dose of irradiation increased the expression of CXCL12, this chemotactic factor might repel the T cells, inducing the tumor invasion; at the same time, the increased expression of CXCL12 induced the tumor angiogenesis. Alternatively, irradiation could increase the expression of HIF-1α, which is highly expressed in hypoxia. The CXCL12 promoter contains 2 HIF-1α binding sites, thus increasing the expression of HIF-1α results in the elevation of CXCL12 levels. Hypoxia can induce the dedifferentiation and stemness of cancer cells \[[@b11-medscimonit-21-1276]\]. CXCL12 has the ability to mediate the survival and proliferation of human progenitor cells. Thus, we though that CXCL12 might mediate the homing of cancer stem cells with the characteristics of radioresistance.

CXCR4, expressed by several cells, is believed as the specific chemokine receptor of CXCL12. The CXCL12/CXCR4 axis plays an important role in tumor growth, metastasis, and angiogenesis. Recently, CXCR7 had also been demonstrated to be another receptor for CXCL12 and to predict poor disease-free and disease-specific survival in cervical cancer patients \[[@b12-medscimonit-21-1276]\]. Thus, there were questions about whether CXCL12 played roles in radioresistance by binding CXCR4 or CXCR7 or both. Another question concerns the signal pathway. In future research we expect to address these questions. Interestingly, we did not find differential expression of CXCR4 or CXCR7 between the tumor tissues before and after radiotherapy, perhaps because irradiation could increase the expression of CXCL12 rather than the expression of its receptors, CXCR4 or CXCR7. Another possibility might be that there was no significant statistical difference between the expression of CXCR4 or CXCR7 before and after radiotherapy.

ATM, firstly described in 1995, was defective in patients with ataxia-telangiectasia. This disease is characterized by cancer susceptibility and profound sensitivity to ionizing radiation \[[@b13-medscimonit-21-1276]\]. ATM, a central kinase involved in the cellular response to DNA double-strand breaks that can lead to the cancer development, could arise when the cells are exposed to ionizing radiation. ATM could regulate DNA damage-induced G2/M cell cycle arrest, which is necessary for DNA repair after irradiation. As this hypersensitivity of ATM-defective cells to ionizing radiation, ATM has drawn research attention as a therapeutic factor for cancer therapy. Several inhibitors of ATM with different limitations have been reported. KU-60019, an ATP-competitive ATM inhibitor reported by Golding et al. \[[@b14-medscimonit-21-1276]\] in 2009, possessed greater potency as a radiosensitizer. They also reported that this ATM inhibitor alone was not toxic for normal brain tissues outside the radiation field. KU-59403, another ATM inhibitor reported by Batey et al. in 2013, also possessed potency as a radiosensitizer and exhibited greater solubility and bio-availability than KU-60019 \[[@b15-medscimonit-21-1276]\]. Although they have significant potency as radiosensitizers, none of these ATM inhibitors are in clinical development at present. In this study, an up-regulated ATM was observed in the residual tumor tissues after radiotherapy. We thought that the increased expression of the ATM gene might play a radioresistant role in advanced cervical cancer.

Proteinases, which are secreted molecules, could degrade various components of the extracellular matrix. Matrix metalloproteinases (MMPs), a kind of proteinase, play an important role in tumor invasion and metastasis via their proteolytic activity. Several studies have shown that irradiation could alter the proteinase activity in tumor cells and tissues \[[@b16-medscimonit-21-1276],[@b17-medscimonit-21-1276]\]. MMP-2 belongs to MMPs, which takes part in extracellular matrix degradation. Up-regulations of MMP-2 in different irradiation conditions have been found in glioblastoma, as well as in colorectal and lung cancer, which leads to enhanced cell invasion \[[@b18-medscimonit-21-1276]--[@b20-medscimonit-21-1276]\]. Park et al. \[[@b21-medscimonit-21-1276]\] found that MMP-2, enhanced by irradiation, was involved in irradiation-induced invasion of glioma cells. Chetty et al. \[[@b22-medscimonit-21-1276]\] also showed that irradiation could increase MMP-2 protein expression and activity in lung cancer cells and that inhibition of MMP-2 could enhance the radiosensitivity. In their study, down-regulation of MMP-2 in the irradiated cells prevented the induction of the FOXM1-mediated DNA repair gene. An up-regulation of MMP-2 was also found in residual cervical cancer tissues after a dose of irradiation in this study. Thus, our results suggested that combined-therapy of MMP-2 inhibitors and irradiation might provide a more effective treatment for advanced cervical cancer.

Path analysis identified some signal pathways in response to irradiation, including cell growth and death, differentiation, cells adhesion and extracellular matrix, Wnt-signaling pathway, TGF-beta signaling pathway, and other signaling pathways that play important roles in tumorigenesis, progression, and invasion. However, the mechanisms of these genes in radiotherapy of advanced cervical cancer still need much clarification.

Conclusions
===========

In this study, we identified dozens of genetic changes in advanced cervical cancer tissues after a dose of irradiation; some of them might be responsible for enhanced metastasis and radioresistance. We found 111 up-regulated genes and 127 down-regulated genes. In future research we plan to validate the functionality of these identified genes. Further research might provide a theoretical basis to develop more effective approaches to improve the radiosensitivity of advanced cervical cancer.
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![Hierarchical clustering map of differential gene expression. The result of hierarchical clustering on conditions shows a distinguishable gene expression profiling among samples. 1\*, 2\*, 3\* means tumor tissues before radiotherapy; 1, 2, 3 means tumor tissues after a 50-Gy dose of radiation of the corresponding patient.](medscimonit-21-1276-g001){#f1-medscimonit-21-1276}

![Quantitative real-time PCR validation of the microarray data. All qRT-PCR data were generally consistent with cDNA microarray data. The relative expression of CXCL12, CD74, COL14A1, and FGF was significantly higher in residual cervical cancer after a 50-Gy dose of irradiation. The relative expression of PRC1 and RAD54L was significantly lower in tumor tissues after radiotherapy. QRTPCR was done in triplicate and the ratio was calculated relative to the reference genes b-action.\*\* P\<0.05 versus control.](medscimonit-21-1276-g002){#f2-medscimonit-21-1276}

![Immunohistochemical staining of CXCL12. A. CXCL12 (brown) expression (++++) in the cell membrane and cytoplasm of cancer cells (×200). B. CXCL12 (brown) expression (+) in the cell membrane and cytoplasm of cancer cells (×200).](medscimonit-21-1276-g003){#f3-medscimonit-21-1276}

![Kaplan-Meier survival analysis of patients with advanced cervical cancer. Kaplan-Meier survival analysis shows that the positive expression of CXCL12 is an independent risk factor in patients with advanced cervical cancer and strongly correlates with poor prognosis.](medscimonit-21-1276-g004){#f4-medscimonit-21-1276}

![Real-time RT-PCR analysis of the expression of CXCL12 in advanced cervical cancer before and after a dose of radiotherapy. Expression of CXCL12 mRNA was measured with quantitative real-time PCR and normalized to b-actin mRNA expression. A significant increasing expression of CXCL12 mRNA was observed in residual cervical cancer. \*\* p\<0.01 compared to tumor tissues before radiation therapy.](medscimonit-21-1276-g005){#f5-medscimonit-21-1276}

###### 

Primer pairs for qRT-PCR.

  --------------------------------------------------------------------------------------
  Gene name   Gene bank ID   Primer sequence from 5′ to 3′         Product length (bp)
  ----------- -------------- ------------------------------------- ---------------------
  CXCL12      NM_199168      F-gattcttcgaaagccatgttg\              136
                             R-cactttagcttcgggtcaatg               

  CD74        NM_004355      F-gaatgctgaccccctgaaggtgta\           396
                             R-gggggctgaagggagcaagaaagc            

  FGF7        NM_002009      F-ggatccatgcaatgacatgactccaga\        507
                             R-aagcttaagttattgccataggaagaaagtggg   

  COL14A1     NM_021110      F-gcgaattccagcagcagggccggct\          480
                             R-ggctcgagtcacatggggactggg            

  PRC1        NM_003981      F-gccaacaaggagaacctgga\               167
                             R-tctcgctgaagcccaacag                 

  RAD54L      NM_001142548   F- gacctttggctcatgggtact\             106
                             R- caggacctgccttcaggttt               
  --------------------------------------------------------------------------------------

###### 

Patients' characteristics.

  Characteristics              N (%)
  ---------------------------- -----------
  Age (year)                   
   \<50                        53 (40.8)
   \>50                        77 (59.2)
  Stage (FIGO)                 
   IIb                         33 (25.4)
   III                         58 (44.6)
   Iva                         39 (30.0)
  Tumor size                   
   \<4 cm                      53 (40.8)
   \>4 cm                      77 (59.2)
  Tumor classification         
   Exogenous                   35 (26.9)
   Endogenous                  30 (23.1)
   Cervical canal              30 (23.1)
   Ulcerative                  35 (26.9)
  Adjuvant therapy             
   None                        59 (45.4)
   Concurrent chemoradiation   71 (54.6)

###### 

Sample qualification.

  Sample ID   A260/ A280   RIN   28S/18S   Result
  ----------- ------------ ----- --------- ------------------
  1           1.93         6.0   0.8       Part degradation
  1\*         1.89         7.7   1.4       Qualified
  2           1.86         7.7   1.3       Qualified
  2\*         1.97         7.2   1.4       Qualified
  3           1.87         7.3   1.0       Qualified
  3\*         1.97         7.1   1.0       Qualified

1\*,2\*,3\* means tumor tissues before radiotherapy; 1, 2, 3 means tumor tissues after 50 Gy dose of radiation of the corresponding patient.

###### 

Up-regulated genes in the residual cervical cancer after 50 Gy dose of radiation at least fivefold higher.

  Gene_symbol    GenBank accession   Description                                                                             Foldchange   *P* values
  -------------- ------------------- --------------------------------------------------------------------------------------- ------------ ------------
  CXCL12         NM_199168           Chemokine (C-X-C motif) ligand 12                                                       34.37257     0.0051
  FYB            NM_199335           FYN binding protein                                                                     21.33432     0.0065
  LOC100506582   XR_109454           Uncharacterized LOC100506582                                                            19.26455     0.0038
  PTGDS          NM_000954           Prostaglandin D2 synthase 21kDa (brain)                                                 18.24440     0.0049
  CHI3L2         NM_004000           Chitinase 3-like 2                                                                      17.63723     0.0090
  COL14A1        NM_021110           Collagen, type XIV, alpha 1                                                             15.4829      0.0001
  SNED1          NM_001080437        Sushi, nidogen and EGF-like domains 1                                                   11.93017     0.0094
  PTPRC          NM_002838           Protein tyrosine phosphatase, receptor type, C                                          11.76348     0.0080
  BHLHE22        NM_152414           Basic helix-loop-helix family, member e22                                               11.05505     0.0072
  HLA-DQA1       NM_002122           Major histocompatibility complex, class II, DQ alpha 1                                  10.89394     0.0039
  MGST1          NM_001260511        Microsomal glutathione S-transferase 1                                                  10.68159     0.0056
  IQGAP2         NM_006633           IQ motif containing GTPase activating protein 2                                         10.67557     0.0052
  FGF7           NM_002009           Fibroblast growth factor 7                                                              10.11275     0.0047
  MRC1           NM_001009567        Mannose receptor, C type 1                                                              9.53875      0.0042
  CASP1          NM_001223           Caspase 1, apoptosis-related cysteine peptidase                                         8.89591      0.0086
  TRIM22         NM_006074           Tripartite motif containing 22                                                          8.77551      0.0094
  CD74           NM_004355           CD74 molecule, major histocompatibility complex, class II invariant chain               8.52676      0.0062
  SELE           NM_000450           Selectin E                                                                              8.26213      0.0015
  HLA-DPB1       NM_002121           Major histocompatibility complex, class II, DP beta 1                                   7.91193      0.0040
  IRAK3          NM_007199           Interleukin-1 receptor-associated kinase 3                                              7.88364      0.0098
  IGDCC4         NM_020962           Immunoglobulin superfamily, DCC subclass, member 4                                      7.52929      0.0005
  KCTD12         NM_138444           Potassium channel tetramerisation domain containing 12                                  7.47977      0.0099
  HLA-DMB        NM_002118           Major histocompatibility complex, class II, DM beta                                     6.91416      0.0076
  PTGFR          NM_001039585        Prostaglandin F receptor (FP)                                                           6.90784      0.0063
  SAMD4A         NM_015589           Sterile alpha motif domain containing 4A                                                6.86448      0.0048
  VWCE           NM_152718           von Willebrand factor C and EGF domains                                                 6.77407      0.0003
  MMP2           NM_004530           Matrix metallopeptidase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)   6.69944      0.0042
  CAPN3          NM_173088           Calpain 3, (p94)                                                                        6.54548      0.0086
  RASA4          NM_001079877        RAS p21 protein activator 4                                                             6.49581      0.0020
  CELF2          NM_001025076        CUGBP, Elav-like family member 2                                                        6.44033      0.0062
  FNBP1          NM_015033           Formin binding protein 1                                                                5.88967      0.0067
  FLI1           NM_002017           Friend leukemia virus integration 1                                                     5.78461      0.0038
  ZMAT1          NM_001011657        Zinc finger, matrin-type 1                                                              5.73992      0.0009
  MICAL1         NM_022765           Microtubule associated monoxygenase, calponin and LIM domain containing 1               5.67725      0.0059
  C1orf38        NM_004848           Chromosome 1 open reading frame 38                                                      5.55259      0.0097
  ARPC4-TTLL3    NM_015644           Tubulin tyrosine ligase-like family, member 3                                           5.52604      0.0016
  IFFO1          NM_001193457        Intermediate filament family orphan 1                                                   5.44289      0.0062
  EPB41L3        NM_012307           Erythrocyte membrane protein band 4.1-like 3                                            5.38832      0.0049
  PPM1K          NM_152542           Protein phosphatase, Mg2+/Mn2+ dependent, 1K                                            5.30152      0.0069
  BIRC3          NM_182962           Baculoviral IAP repeat containing 3                                                     5.26144      0.0018
  PRKCB          NM_212535           Protein kinase C, beta                                                                  5.22640      0.0065
  CREBRF         NM_153607           CREB3 regulatory factor                                                                 5.21976      0.0033
  CLIC2          NM_001289           Chloride intracellular channel 2                                                        5.16835      0.0052
  AMICA1         NM_153206           Adhesion molecule, interacts with CXADR antigen 1                                       5.14923      0.0099
  GAS6           NM_000820           Growth arrest-specific 6                                                                5.12683      0.0048

###### 

Down-regulated genes in the residual cervical cancer after 50 Gy dose of radiation at least fourfold higher.

  Gene_symbol   GenBank accession   Description                                                              Foldchange   *P* values
  ------------- ------------------- ------------------------------------------------------------------------ ------------ ------------
  MEST          NM_177525           Mesoderm specific transcript homolog (mouse)                             19.03931     0.0008
  CDKN3         NM_001130851        Cyclin-dependent kinase inhibitor 3                                      15.72590     0.0079
  HES6          NM_001142853        Hairy and enhancer of split 6 (Drosophila)                               13.30584     0.0035
  CENPN         NM_001100624        Centromere protein N                                                     13.19284     0.0010
  CDC6          NM_001254           Cell division cycle 6 homolog (*S. cerevisiae*)                          12.67188     0.0002
  MCM10         NM_018518           Minichromosome maintenance complex component 10                          12.42256     0.0043
  MND1          NM_001253861        Meiotic nuclear divisions 1 homolog (*S. cerevisiae*)                    12.38095     0.0067
  ZNF367        NM_153695           Zinc finger protein 367                                                  12.13090     0.0004
  GINS1         NM_021067           GINS complex subunit 1 (Psf1 homolog)                                    11.95449     0.0011
  PRC1          NM_003981           Protein regulator of cytokinesis 1                                       11.78833     0.0099
  KIAA0101      NM_014736           KIAA0101                                                                 11.48251     0.0079
  ESCO2         NM_001017420        Establishment of cohesion 1 homolog 2 (*S. cerevisiae*)                  11.18837     0.0085
  FAM64A        NM_019013           Family with sequence similarity 64, member A                             10.46812     0.0044
  TMEM97        NM_014573           Transmembrane protein 97                                                 10.36410     0.0046
  STMN1         NM_203401           Stathmin 1                                                               9.814851     0.0012
  MLF1IP        NM_024629           MLF1 interacting protein                                                 9.786415     0.0005
  TK1           NM_003258           Thymidine kinase 1, soluble                                              9.528579     0.0014
  E2F7          NM_203394           E2F transcription factor 7                                               9.295376     0.0050
  BIRC5         NM_001012270        Baculoviral IAP repeat containing 5                                      9.246912     0.0082
  GINS2         NM_016095           GINS complex subunit 2 (Psf2 homolog)                                    9.024759     0.0030
  FAM111B       NM_001142703        Family with sequence similarity 111, member B                            8.962451     0.0034
  ORC6          NM_014321           Origin recognition complex, subunit 6                                    8.926719     0.0050
  GGH           NM_003878           Gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase)   8.558582     0.0071
  CDC45         NM_001178010        Cell division cycle 45 homolog (*S. cerevisiae*)                         8.505507     0.0098
  PXMP2         NM_018663           Peroxisomal membrane protein 2, 22kDa                                    8.168918     0.0096
  CDT1          NM_030928           Chromatin licensing and DNA replication factor 1                         7.987140     0.0047
  RNASEH2A      NM_006397           Ribonuclease H2, subunit A                                               7.735180     0.0001
  CHML          NM_001821           Choroideremia-like (Rab escort protein 2)                                7.648427     0.0001
  FANCI         NM_001113378        Fanconi anemia, complementation group I                                  7.272155     0.0044
  EXO1          NM_003686           Exonuclease 1                                                            6.787611     0.0037
  RFC4          NM_002916           Replication factor C (activator 1) 4                                     6.678417     0.0062
  C1orf112      NM_018186           Chromosome 1 open reading frame 112                                      6.629925     0.0022
  KLHL23        NM_001199290        Kelch-like 23 (Drosophila)                                               6.565550     0.0088
  ATAD2         NM_014109           ATPase family, AAA domain containing 2                                   6.412012     0.0074
  CCNE1         NM_001238           Cyclin E1                                                                6.285823     0.0003
  KIF15         NM_020242           Kinesin family member 15                                                 6.28417      0.0096
  MCM4          NM_005914           Minichromosome maintenance complex component 4                           6.21293      0.0065
  DSCC1         NM_024094           Defective in sister chromatid cohesion 1 homolog (*S. cerevisiae*)       6.19047      0.0099
  TMEM106C      NM_001143841        Transmembrane protein 106C                                               6.01842      0.0073
  HOMER1        NM_004272           Homer homolog 1 (Drosophila)                                             5.89936      0.0095
  CHEK1         NM_001114121        Checkpoint kinase 1                                                      5.67529      0.0003
  RAD51C        NM_002876           RAD51 homolog C (*S. cerevisiae*)                                        5.62493      0.0020
  MIS18A        NM_018944           MIS18 kinetochore protein homolog A (*S. pombe*)                         5.61498      0.0074
  BRCA1         NM_007294           Breast cancer 1, early onset                                             5.51289      0.0061
  MSH2          NM_000251           MutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)              5.40957      0.0082
  RFC5          NM_001130112        Replication factor C (activator 1) 5, 36.5kDa                            5.40903      0.0081
  VRK1          NM_003384           Vaccinia related kinase 1                                                5.38942      0.0011
  CCDC58        NM_001017928        Coiled-coil domain containing 58                                         5.38923      0.0072

###### 

Correlation between CXCL12 expression and clinicopathological factors in cervical cancer of 130 patients.

                  CXCL12   P    
  --------------- -------- ---- -------
  Age (years)                   0.343
   \<50           27       21   
   \>50           53       29   
  FIGO stage                    0.449
   II             22       14   
   III            31       24   
   IV             27       12   
  Tumor size                    0.512
   \<4 cm         34       19   
   \>4 cm         45       32   
  Treatment                     0.504
   Radiotherapy   34       25   
   CCRT           45       26   

###### 

Univariate and multivariate Cox regression analysis of prognostic factors.

  Clinicopathological characteristics   n (n=130)   5-year survival rate   Kaplan-Meier analysis   Cox regression model analysis           
  ------------------------------------- ----------- ---------------------- ----------------------- ------------------------------- ------- -------
  Age (years)                                                                                                                              
   \<40                                 48          31.6                                                                                   
   ≥40                                  82          44.0                   2.284                   0.131                           0.147   0.702
  FIGO stage                                                                                                                               
   II b                                 36          53.5                                                                                   
   III                                  55          40.6                                                                                   
   IV a                                 39          25.2                   8.108                   0.017                           6.272   0.012
  Tumor size                                                                                                                               
   \<4 cm                               53          41.2                                                                                   
   ≥4 cm                                77          39.3                   0.432                   0.511                           0.228   0.633
  Treatment                                                                                                                                
   Radiotherapy                         59          28.4                                                                                   
   CCRT                                 71          48.1                   5.983                   0.014                           5.423   0.020
  CXCL12 expression                                                                                                                        
   Positive                             79          30.0                                                                                   
   Negative                             51          52.7                   4.305                   0.038                           4.451   0.035

CCRT -- concurrent chemoradiation.
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